BOARD OF TRUSTEES OF THE UNIVERSITY
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $72.1M
- Transactions
- 4,055
- Companies
- 40
- Average per transaction
- $17,781
Who reported the payments
| Novartis | $16,183,245 |
| Intuitive Surgical | $5,422,181 |
| CSL Behring | $5,105,303 |
| Eli Lilly | $3,796,142 |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,345,485 |
| Pfizer | $2,886,675 |
| Medtronic | $2,867,054 |
| Boehringer Ingelheim | $2,165,482 |
| Gilead | $2,114,181 |
| AbbVie | $2,070,235 |
| Genentech, Inc. | $1,760,131 |
| Merck | $1,552,258 |
| Amgen | $1,037,926 |
| Janssen Research & Development, LLC | $1,008,562 |
| F. Hoffmann-la Roche AG | $968,367 |
| Vanda Pharmaceuticals Inc. | $936,910 |
| Jazz Pharmaceuticals Inc. | $797,497 |
| Solventum Corporation | $776,933 |
| Abbott | $776,007 |
| E.r. Squibb & Sons, L.L.C. | $696,820 |
| Regeneron | $678,252 |
| Alcon Research LLC | $632,800 |
| Iovance Biotherapeutics, Inc. | $585,759 |
| Eisai Inc. | $535,332 |
| Incyte Corporation | $534,570 |
| Global Blood Therapeutics, Inc. | $522,810 |
| Dentsply IH Sweden | $490,746 |
| Sanofi | $458,462 |
| Sanofi US Services Inc. | $428,711 |
| Tanabe Pharma America, Inc. | $410,110 |
| Smith+Nephew | $379,354 |
| Alnylam Pharmaceuticals Inc. | $362,098 |
| AstraZeneca | $344,498 |
| Seagen Inc. | $317,440 |
| Astellas Pharma Global Development | $314,944 |
| Shionogi Inc | $309,743 |
| Siemens Medical Solutions USA, Inc. | $302,740 |
| Bristol Myers Squibb | $288,085 |
| Dentsply IH AB | $272,847 |
| Teva Pharmaceuticals USA, Inc. | $263,828 |